Ocera Therapeutics Announces Staffing Transition
PALO ALTO, Calif., Dec. 11, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics
(Nasdaq:OCRX) today announced that David S. Moore, its chief business officer,
will be leaving Ocera to pursue other opportunities. Mr. Moore was a former
member of the management team at Tranzyme and continued his employment with
Ocera following the merger of Ocera and Tranzyme, which closed in July 2013.
"We are grateful to David for his leadership in overseeing several aspects of
our post-merger integration and streamlining," said Linda Grais, M.D., chief
executive officer of Ocera. "We wish him the best in his future endeavors."
"It has been exciting to be part of a successful merger process, from the
initial concept through completion of full integration. OCR-002 has great
therapeutic potential for patients with liver disease, which is an important
and growing market," said David Moore. "However, my background lies in sales
and marketing, and I plan to return to working with commercial stage
In addition, as part of the transition of Ocera's corporate headquarters to
Palo Alto, CA, Rhonda L. Stanley, Ocera's controller and principal accounting
officer will be leaving Ocera. Jeryl L. Hilleman, Ocera's chief financial
officer will assume the role of principal accounting officer effective
immediately and a controller has been hired in Palo Alto.
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused
on the development and commercialization of OCR-002 (ornithine phenylacetate).
OCR-002 is an ammonia scavenger which has been granted Orphan Disease and Fast
Track status from the FDA to treat hyperammonemia and associated hepatic
encephalopathy in patients with liver cirrhosis, acute liver failure and acute
liver injury. For additional information, please see www.ocerainc.com.
Forward Looking Statements
This press release contains "forward-looking" statements, including, without
limitation, all statements related to the OCR-002 clinical development
program, including the market size of patients with liver disease and the
potential success of OCR-002 in clinical trials. Any statements contained in
this press release that are not statements of historical fact may be deemed to
be forward-looking statements. Words such as "believe," "expected," "hope,"
"plan," "potential," "will" and similar expressions are intended to identify
forward-looking statements. These forward-looking statements are based upon
Ocera's current expectations. Forward-looking statements involve risks and
uncertainties and Ocera's actual results and the timing of events could differ
materially from those anticipated in such forward-looking statements as a
result of these risks and uncertainties, including those risks and
uncertainties discussed under the heading "Risk Factors" in Ocera's Quarterly
Report on Form 10-Q for the quarter ended September 30, 2013 filed on November
14, 2013, as well as other risks detailed in Ocera's subsequent filings with
the Securities and Exchange Commission. All information in this press release
is as of the date of the release, and Ocera undertakes no duty to update this
information unless required by law.
Ocera Therapeutics, Inc.
Press spacebar to pause and continue. Press esc to stop.